warning_amberWhat You Should Know

GLP-1 Shortage Status in 2026

What the FDA shortage list is, why GLP-1s ended up on it, when they came off, and what 'resolved' actually means for patients and compounded products.

The FDA's drug shortage list shaped the GLP-1 market for two years. While semaglutide and tirzepatide were officially listed, federal law allowed compounding pharmacies to prepare them. When the FDA declared the shortages resolved in late 2024, that legal cover ended after short transition windows.

This guide walks through how the shortage list works, the timeline for the GLP-1 entries, and what the current "resolved" status means in practical terms for patients, prescribers, and the compounded market. It also flags where the situation could still change — shortage status is not permanent, and supply concerns can re-emerge.

Sources and dates in this article are accurate as of May 2026. Confirm the current status with the FDA Drug Shortages database before making a clinical or financial decision based on it.

What the FDA shortage list is

The FDA's drug shortage database tracks medications where current supply is not meeting current demand. Drugs land on the list based on confirmed reports from manufacturers, distributors, prescribers, and pharmacies. A shortage listing is not just informational — it carries specific legal consequences. The most relevant for GLP-1s: under federal compounding law (Section 503A of the Federal Food, Drug, and Cosmetic Act), a compounding pharmacy may not prepare a copy of an FDA-approved product unless that product is on the FDA's shortage list. While a drug is listed, this prohibition is suspended.

This is the mechanism that allowed compounded semaglutide and tirzepatide to be sold at scale in 2022–2024. When those drugs came off the shortage list, the suspension lifted, and compounding pharmacies were generally barred from preparing copies for routine use.

The GLP-1 shortage timeline

Semaglutide products (Ozempic and Wegovy) were added to the shortage list in August 2022 as demand outpaced Novo Nordisk's manufacturing capacity. Tirzepatide products (Mounjaro and Zepbound) were added in December 2022 under similar pressure as Eli Lilly's pens hit the market.

Both manufacturers invested heavily in expanding capacity. By 2024, Eli Lilly publicly stated it had met U.S. demand for tirzepatide. Novo Nordisk made similar statements about semaglutide later that year.

The FDA declared the tirzepatide shortage resolved in October 2024. Compounding industry groups sued to delay enforcement; the FDA paused briefly and then issued a final clarifying decision in December 2024. Short transition windows followed — 503A pharmacies were generally expected to stop compounding tirzepatide within roughly 60 days of the final notice, and 503B outsourcing facilities had a slightly longer runway.

The semaglutide shortage was declared resolved in October 2024 as well, with a similar transition pattern. By mid-2025, both shortages had been off the list long enough that broad commercial compounding of either drug had largely ended.

As of 2026, semaglutide and tirzepatide are not on the FDA's drug shortage list for routine commercial purposes. Some patient-specific compounding may still occur for documented clinical needs (such as allergies to inactive ingredients in the approved products), depending on the state and current FDA enforcement priorities.

What "resolved" actually means

"Resolved" in the FDA's terminology means that current supply meets current demand for the product as a whole. It does not mean that every dose strength of every pen is in stock at every pharmacy at every moment. Localized shortages — a specific dose being temporarily unavailable at a specific pharmacy — can still happen and do not put a drug back on the FDA list.

For patients, "resolved" means:

The drug is no longer in federal shortage status.
Compounding pharmacies generally cannot prepare it for routine use.
The manufacturer is the primary commercial source again — through retail pharmacies, mail-order, and their direct-to-consumer self-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound).

It does not mean:

Brand-name prices have come down (they have not).
Every dose is always available everywhere (occasional pharmacy-level back-orders still happen).
Compounded versions are illegal to possess (they are not — they were just produced under a legal framework that no longer applies broadly).

What patients are doing as a result

Practical paths in 2026

card_membership

Manufacturer savings card

If you have commercial insurance that covers Wegovy or Zepbound, the manufacturer savings card brings out-of-pocket to as little as $25/month, subject to monthly and annual caps. Government insurance (Medicare, Medicaid, TRICARE) is excluded by federal anti-kickback rules.

local_shipping

Manufacturer self-pay

Cash-pay patients can use NovoCare Pharmacy for Wegovy (around $349/month) or LillyDirect for Zepbound vials ($299–$449/month depending on strength). Both are FDA-approved products shipped from the manufacturer.

support_agent

Patient assistance

Novo Nordisk and Eli Lilly both run income-tested patient assistance programs that provide medication at no cost or deeply reduced cost to qualifying low-income patients without insurance.

Common questions

Common Concerns

Is semaglutide in shortage in 2026?expand_more

No — the FDA declared the semaglutide shortage resolved in October 2024 and it has not returned to the shortage list as of May 2026. Localized back-orders at specific pharmacies can still happen but do not constitute a national shortage. Confirm current status at the FDA Drug Shortages database before relying on this.

Is tirzepatide in shortage in 2026?expand_more

No — the FDA declared the tirzepatide shortage resolved in October 2024, with final clarifying guidance issued in December 2024. The drug has not returned to the shortage list as of May 2026. Verify current status at the FDA Drug Shortages database.

If I'm still getting compounded GLP-1 in 2026, what does that mean?expand_more

With both shortages resolved, broad commercial compounding of semaglutide and tirzepatide for routine weight management is no longer protected by federal law. Patient-specific compounding for documented clinical needs (allergies to inactive ingredients, very non-standard doses) may still occur case-by-case. If a pharmacy is still selling compounded GLP-1s to general weight-management patients without a documented clinical exception, verify their licensing status with your state board of pharmacy.

Could GLP-1s go back on the shortage list?expand_more

Yes — shortage status can change. If manufacturer supply slips behind demand again, the FDA can re-list a drug. That would, in principle, re-open the legal window for compounding. Whether it would happen depends on manufacturing capacity, demand growth, and how the FDA evaluates the supply situation at that point.

Where can I check the current shortage status?expand_more

The FDA Drug Shortages database is the authoritative source. Search for the product name (e.g., 'semaglutide' or 'tirzepatide'). Manufacturer-specific notices are also posted by Novo Nordisk and Eli Lilly. State boards of pharmacy can also clarify whether compounding is permitted in your state.

Keep exploring

Browse all dosing guides.